First Human Trial of Reverse-Aging Cellular Reprogramming Treatment Begins
Life Biosciences has dosed the first human participant in a clinical trial testing ER-100, a gene therapy designed to partially reprogram aged cells in the eye to a more youthful state, targeting glaucoma and a related optic nerve condition. The Boston-based company, co-founded by Harvard geneticist David Sinclair, uses three of the four so-called Yamanaka factors — proteins that can reset a cell's epigenetic state — delivered via a viral vector and activated by a daily antibiotic. The trial marks the first time epigenetic reprogramming has been tested in humans, a milestone with broad implications for aging biology, though significant safety concerns, including cancer risk, remain unresolved.
Life Biosciences announced that its first participant has received an injection of ER-100 (AAV2-OSK), an experimental gene therapy that activates three genes — Oct4, Sox2, and Klf4 — to partially reprogram retinal ganglion cells in the optic nerve, which are damaged in glaucoma and do not naturally regenerate. The FDA approved the therapy for its first clinical trial in January 2026, and the Phase 1 study will enroll up to 18 participants with either open-angle glaucoma or non-arteritic anterior ischemic optic neuropathy (NAION), two conditions that cause progressive and often irreversible vision loss. The therapy uses a non-infectious viral vector to deliver genetic instructions, with gene activation controlled by a doxycycline-based on/off switch, allowing researchers to halt reprogramming if safety concerns arise. Preclinical studies in rodents and non-human primates showed no serious adverse effects, and the eye was chosen as a first target partly because it is semi-isolated, limiting the risk of systemic side effects. The primary goal of this first trial is to assess safety, though vision outcomes will also be tracked, with participants followed for at least five years. The trial arrives amid a broader surge of investment in cellular reprogramming, with billions of dollars flowing to companies such as Altos Labs, Retro Biosciences, and NewLimit, all pursuing similar approaches for different tissues and diseases. Critics, including stem cell biologist Paul Knoepfler, warn that the therapy carries high risks, including the potential to push cells into a cancerous state, and question whether it is ready for human testing.
What's missing
The sources do not specify the dosing regimen or duration of the doxycycline antibiotic protocol required to activate the therapy, nor do they clarify what measurable vision outcomes or biomarkers will define success or failure in this Phase 1 trial beyond general safety monitoring.
How coverage differed
Business Insider framed the trial primarily through the lens of billionaire investment and longevity hype, emphasizing figures like Jeff Bezos and Sam Altman and describing the moment as potentially 'transformational for medicine,' while Nature News and ScienceAlert gave more weight to scientific skepticism, quoting researchers who called the approach 'extraordinarily high-risk' and cautioning that 'a lot can go wrong.' MIT Technology Review provided the most analytical framing, contextualizing reprogramming within the broader history of aging research trends and noting that prior hyped approaches, such as senolytics, have so far disappointed in human trials.
What different sources said
- ScienceAlertCenter
World First: Patient Receives High-Risk Therapy to Make Cells Young Again
- Business InsiderLeft
The first-ever reverse-aging drug was just injected into a human
- Science DailyCenter
Scientists discover a hidden cause of aging cells that can be reversed
- Medical XpressCenter
Novel gene therapy platform restores muscle function in Duchenne muscular dystrophy model
- Mirage NewsCenter
Gene Therapy Restores Muscle in Duchenne Models
- Nature NewsCenter
World-first: therapy to make cells young again given to a person
- EuronewsCenter
Is it possible to rejuvenate damaged human cells? US biotech firm tests new gene therapy
- MIT Technology ReviewCenter
Why “reprogramming” is the buzziest approach to reversing aging right now
- Scientific AmericanCenter
World-first: therapy to make cells young again given to a person
Related
Chicago Woman's Five-Year Symptom Journey Leads to Rare Brain Tumor Diagnosis
Melony Aponte, 26, was diagnosed with a 4.5-centimeter acoustic neuroma after five years of symptoms she attributed to stress, COVID-19, and aging. The rare, noncancerous tumor—affecting roughly one in 100,000 people—had grown large enough to compress her hearing and balance nerve before it was identified via MRI in March 2025. Her case highlights how acoustic neuroma symptoms can mimic common conditions, potentially delaying diagnosis for years.
Study Finds Aging Shifts Walking Strategy Toward Stability at the Cost of Efficiency
A new study from Flinders University and the University of Canberra found that as people age, their bodies adopt a 'safety-first' walking pattern that prioritizes balance over efficient movement. Researchers analyzed gait data from 107 healthy adults aged 26 to 86, identifying increased ankle muscle co-contraction and reduced push-off power as key age-related changes. The findings suggest that fall prevention programs should target balance and coordination, not just muscle strength.
Tick Populations Surge in Urban Areas Across Northeast
Experts across the northeastern United States and Canada are warning of an unusually early and widespread tick season, with disease-carrying ticks increasingly found in urban parks and green spaces. Lyme disease cases in Canada reached a record 7,105 in 2025, up from 5,809 the previous year, while U.S. cities including Philadelphia, Pittsburgh, Washington D.C., and New York are reporting rising tick activity. The expansion poses a public health challenge because urban residents are less likely to take tick-bite precautions than those in rural areas.